Dabur India Limited has issued a clarification regarding a news item about the USFDA flagging data integrity and maintenance lapses at its Silvassa plant. The company stated that the observations pertain to a small part of the manufacturing facility that generates insignificant revenue. The plant remains operational, and Dabur is actively working with the USFDA on a corrective action plan. The company reaffirmed its commitment to quality and stated there is no financial or operational impact.
Dabur Responds to USFDA Audit News
Dabur India Limited has provided a clarification concerning a recent news item, dated May 29, 2026 and May 30, 2026, which reported on findings from the United States Food & Drug Administration (USFDA) at one of its manufacturing plants. The announcement, dated June 01, 2026, addresses concerns raised regarding data integrity and maintenance lapses.
Details of USFDA Observations
The company stated that the observations provided by the USFDA relate to a small part of its manufacturing plant located in Silvassa, Dadra and Nagar Haveli. This specific facility contributes insignificant revenue to the overall company’s operations. Crucially, Dabur India confirmed that the aforementioned plant continues to be operational.
Corrective Actions and Commitment to Quality
Dabur India is actively engaged with the USFDA concerning these findings. The company has developed and is implementing a robust corrective and preventive action plan to address the concerns raised. Updates on the progress of this plan are being regularly shared with the USFDA. Dabur reiterated its commitment to maintaining the highest standards of product quality across all its manufacturing sites, ensuring that quality systems are never compromised and consumers receive optimal experiences.
No Financial or Operational Impact
The company emphasized its unwavering commitment to quality, safety, and compliance in all its products and manufacturing processes. All products are manufactured and delivered with the highest levels of quality and hygiene, in strict compliance with applicable regulations. As of the date of this announcement, Dabur confirmed that there is no impact on the company’s financial performance, operations, or any other activities resulting from the USFDA observations. Furthermore, there are no other material events or information requiring disclosure under the relevant regulations.
The information provided in this announcement will also be made available on the company’s official website, www.dabur.com.
Source: BSE
